BioMarin Pharmaceutical Inc. buy UBS Group AG
Start price
20.02.25
/
50%
€65.70
Target price
20.02.26
€108.05
Performance (%)
-18.54%
End price
21.02.26
€53.52
Summary
This prediction ended on 21.02.26 with a price of €53.52. The price of BioMarin Pharmaceutical Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -18.54%. UBS_Group_AG has a follow-up prediction for BioMarin Pharmaceutical Inc. where he still thinks BioMarin Pharmaceutical Inc. is a Buy. UBS_Group_AG has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| BioMarin Pharmaceutical Inc. | 2.356% | 2.356% | 5.452% |
| iShares Core DAX® | 2,99 % | 3,22 % | 4,27 % |
| iShares Nasdaq 100 | -1,58 % | -3,17 % | 24,75 % |
| iShares Nikkei 225® | -2,25 % | -9,92 % | 43,52 % |
| iShares S&P 500 | -0,01 % | 1,64 % | 20,97 % |
Comments by UBS_Group_AG for this prediction
In the thread BioMarin Pharmaceutical Inc. diskutieren
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at UBS Group AG from $109.00 to $113.00. They now have a "buy" rating on the stock.
Ratings data for BMRN provided by MarketBeat
In the thread Trading BioMarin Pharmaceutical Inc.
Die von UBS_Group_AG gewählte maximale Laufzeit wurde überschritten
Current prediction by UBS_Group_AG for BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€51.06
05.08.25
05.08.25
€98.62
05.08.26
05.08.26
3.80%
27.07.26
27.07.26
Stopped prediction by UBS_Group_AG for BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€62.34
30.10.24
30.10.24
€97.65
30.10.25
30.10.25
-28.01%
31.10.25
31.10.25